TIME Best Inventions honors extraordinary innovations changing lives , /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for people with Parkinson's – has been recognized by TIME on its annual list of Best Inventions. There are over 10 million people living with Parkinson's disease globally,and while there is currently no cure, Medtronic deep brain stimulatio ...

MESA, ARIZONA / ACCESS Newswire / October 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a developer of artificial intelligence-powered preventive health technology, today emphasized the urgent human need driving each vertical of its AI platform - underscoring the global lives lost and affected every year to conditions that may be better managed through earlier detection and awareness. Skin Health Over 60,000 people die from melanoma and other skin cancers each year. ...

MAULDIN, SC / ACCESS Newswire / October 9, 2025 / Xcelerate, Inc. (OTC Markets:XCRT) today announced the sale of its majority interest in the ESN Group of companies, including ESN Group, Inc. and California Skin Research, Inc to Noble Labs Holdings, LLC, a company that had previously provided funding and marketing support to ESN Group, Inc. The transaction was completed as an all-cash sale. "We made a decision to divest these assets in order to re-focus our business on our original mission of implementing a ...

Nexalin Technology Inc. (NASDAQ:NXL) stock spiked on Wednesday, with a massive session volume of 167.9 million compared to the average volume of 972.2 thousand, as per data from Benzinga Pro.The company announced the publication of additional positive clinical data in Radiology demonstrating that its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS technology—Nexalin’s advanced implementation of transcranial alternating current stimulation (tACS)—improves cognitive performance and enhances brain network conn ...

Core Insights - Tilray Brands (TLRY) is set to report its first-quarter fiscal 2026 results on October 9, 2025, before market opening [1] - The company reported fourth-quarter fiscal 2025 adjusted earnings of 2 cents per share, exceeding the Zacks Consensus Estimate by 166.67% [1] - TLRY has beaten earnings estimates in two of the last four quarters and missed in the other two [1] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues in the upcoming quarter is $206.8 million, indicating a 3.4% increase from the previous year [2] - The loss per share estimate is set at 3 cents, reflecting a 25% year-over-year increase [2] - Estimates for loss per share have remained unchanged at 3 cents over the past 30 days [3] Factors Influencing Performance - **Cannabis Segment**: In the fourth quarter of fiscal 2025, cannabis net revenues declined year-over-year due to a pause in vape and infused pre-roll categories and delays in international medical cannabis permits. However, international cannabis revenues reached a record high of $22.4 million, with Germany showing 134% growth [4] - **Tilray Medical**: The division introduced three new medical cannabis flower varieties in Italy, becoming the first authorized company to import and distribute its products there. A strategic partnership with Molteni aims to enhance the availability of Tilray Medical cannabis extracts in Italy, expected to boost top-line growth [5] Segment Performance Expectations - **Beverages**: The Beverages segment is anticipated to see a revenue decline due to SKU rationalization under Project 420. However, the Breckenridge Distillery brand is expected to show resilience in the bourbon sector [8][10] - **Wellness**: The Wellness segment is projected to experience a year-over-year revenue surge, driven by the growth of Manitoba Harvest Hemp Hearts and new product innovations [11] - **Distribution**: Distribution revenues, primarily from Tilray Pharma, are expected to grow due to changes in product mix [12] Earnings Outlook - Tilray Brands has an Earnings ESP of 0.00%, indicating no expected earnings surprise for the upcoming report [13] - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [13]

UPPSALA, SE / ACCESS Newswire / October 8, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ) today announced the launch of EMGINETM, a proprietary software suite for its next-generation TetraGraph® platform. The new technology will be unveiled at the ANESTHESIOLOGY® 2025 conference, taking place October 11-13 in San Antonio, Texas, USA. ...

New York, NY, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that on October 4, 2025, it caused to be deposited $0.15 per public share, totaling $10,890.15 (the “Extension Payment”) into its trust account (the “Trust Account”) with Continental Stock Transfer and Trust Company (“Continental”) to extend the deadline to complete its initial business combination from October ...

MESA, ARIZONA / ACCESS Newswire / October 7, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging innovator in AI-driven preventive healthcare, today announced its strategic plan to separate its artificial intelligence health applications into two distinct divisions - one designed for clinical validation and regulatory approval, and another tailored for consumer and research-based wellness monitoring. The company's proprietary platform integrates multiple diagnostic and predictive modules powe ...

VANCOUVER, BC – October 7, 2025 – TheNewswire - Dova Health Intelligence Inc., a leader in AI-driven gastrointestinal disease assessment, is pleased to announce a collaboration with Mayo Clinic to advance the development and validation of DovaVision UC Mayo Endoscopic Score (MES), an artificial intelligence tool designed for more precise and reproducible scoring of ulcerative colitis disease activity from colonoscopy videos. Evaluating mucosal healing accurately is a critical element in the management of in ...

PITTSBURGH , Oct. 7, 2025 /PRNewswire/ --Â Catalyst MedTech today announced the launch of its new Connect program, an initiative that brings together collaborators seeking to advance patient care with the access required to make it possible. Connect leverages Catalyst's unique dual business structure—Equipment Solutions and Clinical Solutions—to deliver customizable pathways that expand access to diagnostic imaging and treatment. ...